New Frontiers in Immunotherapy: Checkpoint Inhibitors Beyond CTLA-4 and PD-1

Recent Trends in Checkpoint Inhibitor Research

Over the past several years, the field of cancer immunotherapy has expanded beyond the established CTLA-4 and PD-1/PD-L1 axes. Investigators are now focusing on a broader set of immune checkpoints, including LAG-3, TIGIT, VISTA, and TIM-3, with several agents entering late-stage clinical evaluation. The emphasis has shifted from single-agent monotherapy to rational combination strategies that target multiple, non-redundant pathways. Dual checkpoint blockade—such as combining anti–LAG-3 with anti–PD-1—has shown improved response rates in certain tumor types, though with an increased burden of immune-related adverse events. Biomarker-driven patient selection is also gaining traction, with tumor mutational burden, microsatellite instability, and tumor-infiltrating lymphocyte profiles being used to identify likely responders.

Background: From Established Checkpoints to New Targets

CTLA-4 and PD-1 inhibitors were the first immune checkpoint blockades approved, demonstrating durable responses in melanoma, non–small cell lung cancer, renal cell carcinoma, and other malignancies. However, many patients either do not respond or develop acquired resistance. This has driven the investigation of alternative checkpoints that either limit T-cell activation in the tumor microenvironment or modulate other immune cell types. Key emerging targets include:

• LAG-3 – Co-expressed with PD-1 on exhausted T cells; dual inhibition has shown superior efficacy in melanoma compared to PD-1 blockade alone.
• TIGIT – Expressed on T cells and NK cells; its blockade combined with PD-(L)1 inhibition is being tested in NSCLC, small cell lung cancer, and colorectal cancer.
• TIM-3 – Marked on dysfunctional T cells; trials are exploring combinations with anti–PD-1 in hematologic and solid tumors.
• VISTA – A myeloid checkpoint that suppresses T-cell activity; preclinical and early clinical data suggest utility in prostate and ovarian cancers.
• B7-H3 and B7-H4 – Overexpressed on tumor cells and stromal cells; antibody–drug conjugates and bispecifics are in development to redirect immune attack.

The mechanistic rationale for targeting these checkpoints lies in their role in tumor immune evasion, often in parallel with PD-1/PD-L1 signaling. Combinations aim to reinvigorate exhausted T cells while also engaging innate immunity.

User Concerns Among Oncology Professionals

Clinicians and researchers have raised several practical and safety-related concerns about these new agents:

• Toxicity management – Dual checkpoint blockade amplifies autoimmune-type adverse events, including colitis, pneumonitis, endocrinopathies, and cutaneous reactions. Guidelines from professional societies recommend early, proactive monitoring and a low threshold for steroid use, but management protocols for newer combinations are still being refined.
• Biomarker validation – Many emerging checkpoint inhibitors lack validated companion diagnostics, making patient selection uncertain. Labs may rely on immunohistochemistry scoring or gene expression signatures that have not been standardized across platforms.
• Cost and access – Combination regimens are costly, and reimbursement criteria often lag behind approval. Professionals must weigh incremental benefit against financial toxicity, especially in health systems with fixed budgets.
• Resistance mechanisms – Even combined blockade may fail when tumors employ alternative immune-evasive pathways (e.g., upregulation of other checkpoints, loss of antigen presentation, or exclusion of T cells). Strategies to overcome these, such as adding oncolytic viruses or metabolic modulators, are still experimental.
• Comparative effectiveness – Without head-to-head trials, it is difficult to determine whether a LAG-3/PD-1 combination offers advantage over a PD-1/CTLA-4 regimen in the same indication. Network meta-analyses and real-world evidence are increasingly used to guide clinical decisions.

Likely Impact on Clinical Practice and Research

The introduction of checkpoint inhibitors beyond CTLA-4 and PD-1 is reshaping treatment algorithms in several ways:

• Expansion of first-line options – In melanoma, the combination of nivolumab with relatlimab (anti–LAG-3) has already received regulatory approval. Similar approvals may follow for TIGIT and TIM-3 inhibitors in lung and gastrointestinal cancers.
• Shift toward rational combinations – Rather than broad immunotherapy cocktails, future trials will increasingly rely on tumor- and immune-phenotyping to select dual or triple combinations tailored to a patient’s immune profile.
• Integration with other modalities – These checkpoint inhibitors are being combined with radiation, chemotherapy, targeted therapy, and cellular therapies. For example, TIGIT blockade may enhance NK cell activity when used with ADCC-competent antibodies.
• Increased emphasis on immune monitoring – Serial biopsies and peripheral blood immune assays will become standard in clinical trials to track dynamic changes in T cell exhaustion, clonal expansion, and myeloid cell activity.
• Potential for off-the-shelf cell therapies – Bispecific molecules that simultaneously block checkpoints and engage T cells (e.g., bispecific antibodies targeting PD-1 and CTLA-4, or CD3 and B7-H3) are being developed as alternatives to checkpoint inhibitors.

What to Watch Next

Professionals should monitor the following developments over the next 12–24 months:

• Phase III readouts for TIGIT and LAG-3 in front-line NSCLC and gastric cancer. The durability of response and impact on overall survival will determine whether these agents become standard of care.
• Regulatory decisions for dual checkpoint fixed-dose combinations, particularly from the FDA and EMA, which may simplify administration but also raise questions about dose flexibility.
• Biomarker standardization efforts by organizations such as ASCO, ESMO, and the CAP, which aim to provide consensus definitions for LAG-3 positivity and TIGIT expression.
• Early data on myeloid checkpoint inhibitors targeting VISTA, CD47, and CSF1R. These may offer new options for “cold” tumors that resist T-cell–based therapies.
• Real-world safety registries for newer combinations, as post-marketing surveillance will reveal rare or delayed adverse events not captured in trials.
• Economic analyses from health technology assessment bodies that compare cost-effectiveness of novel checkpoint combinations against existing PD-1/CTLA-4 regimens.

As the immunotherapy landscape grows more complex, oncology professionals will need to remain agile in interpreting emerging evidence, integrating biomarker data, and balancing efficacy with safety and cost. The next generation of checkpoint inhibitors promises to extend the reach of immunotherapy to a broader patient population, but careful validation and thoughtful clinical implementation are essential.